

siRNA	CD41+ (%)	CD41+ (MFI)
CTL	91.8 ± 0.7	6522.6 ± 573.2
TLN1	93.1 ± 2.3	6409.0 ± 549.1
FLNA	92.8 ± 1.8	6346.0 ± 568.4
TLN1 + FLNA	91.8 ± 0.5	6427.0 ± 511.8

The mean percentage of CD41+ cells and mean fluorescence intensity (MFI) ± SD from 3 independent experiments are represented.

Fig. S5. Additional controls demonstrating the co-expression of chimeric integrins and siRNAs in cells adhered to fibrinogen. (A-C) CHO K1 cells were transiently transfected with control siRNA, talin1 siRNA, FLNa siRNA or with both talin1 and FLNa siRNAs for 48 hours and then co-transfected for 24 hours with expression vectors for the αIIb-ΔL and β3-1AWT integrin subunits. Transfected cells were replated on fibrinogen for 1 hour in CCM1 and then collected to demonstrate (1) that adhesion to fibrinogen selects for cells expressing the chimeric integrin and (2) that these adherent cells show the inhibition of talin1 and/or FLNa expression depending upon the siRNA(s) used. (A-B) FACS analysis using an antibody to CD41 (PC5), which recognizes the αIIb-β3 extracellular complex, indicated that recombinant integrin expression was not altered by depleting cells of talin1 and/or FLNa and that adhering transiently transfected cells to fibrinogen enriches for cells expressing the chimeric integrin. Data represents the percentage (%) and mean fluorescence intensity (MFI) for each condition. (C) The knockdown of talin1 and FLNa in cells replated onto fibrinogen was confirmed by western blotting. Plotted are the average expression levels for talin1 (left) and FLNa (right) ± s.d. from the 3 independent experiments shown in A, together with representative western blots. Effects on spreading were similar to those presented in previous experiments (data not shown).